Compounded semaglutide vs. Ozempic for type 2 diabetes

Ozempic's label lists three jobs, all in adults with type 2 diabetes: improving blood sugar alongside diet and exercise, reducing major cardiovascular events in people with established heart disease, and reducing sustained kidney decline, kidney failure and cardiovascular death in people with chronic kidney disease. It comes as a pen dialled to 0.25, 0.5, 1 or 2 mg once a week, and since May 2026 also as a daily Ozempic pill (1.5, 4 and 9 mg).

A compounded semaglutide has none of those indications. It is a pharmacy preparation for one prescription, usually a multi-dose vial you draw with an insulin syringe, at a concentration the pharmacy chose. That gap matters more in diabetes than in weight management, because the dose interacts with insulin or sulfonylureas you may also take, and your HbA1c, not the scale, is the result being tracked.

No study has compared a compounded preparation with Ozempic, in diabetes or anything else. What Ozempic has is outcome evidence that is unusually specific to people with diabetes:

• SUSTAIN-6 (NEJM 2016): in adults with type 2 diabetes at high cardiovascular risk, the primary cardiovascular outcome occurred in 6.6% on semaglutide against 8.9% on placebo, a hazard ratio of 0.74.
• FLOW (NEJM 2024): in type 2 diabetes with chronic kidney disease, semaglutide 1 mg lowered the risk of the primary kidney outcome by 24%, which is the basis of the kidney indication now on the label.

Those are hard-outcome trials, run on the manufactured pen at label doses. The often-quoted weight figures belong elsewhere: the 14.9% average in STEP 1 came from 2.4 mg in people without diabetes, a dose above Ozempic's 2 mg ceiling. For a compounded vial, the relevant evidence is FDA's: it cannot verify quality, safety or effectiveness before sale, and it has received reports of hospitalisations linked to dosing errors with compounded injectable semaglutide.

Ozempic's label lists nausea, vomiting, diarrhoea, abdominal pain and constipation as the reactions seen in at least 5% of people. For someone with diabetes, three warnings deserve extra attention. Hypoglycaemia becomes a real risk when semaglutide is combined with insulin or a sulfonylurea, and the label says those doses may need reducing. Diabetic retinopathy complications were reported in a trial, so anyone with existing eye disease should be monitored. Acute kidney injury can follow dehydration from vomiting or diarrhoea, which matters more when kidney function is already reduced.

The boxed warning on thyroid C-cell tumours in rodents applies to every semaglutide product. With a compounded vial, add one more: a units error that doubles your dose also raises the chance of low blood sugar if you take other glucose-lowering drugs.

If you have type 2 diabetes, Ozempic is the product built for you. It carries the heart and kidney indications, it is an approved diabetes drug that a plan can cover for that use, and its self-pay price has fallen: NovoCare Pharmacy lists $199 a month for the first two fills of the 0.25 and 0.5 mg pens, then $349 up to 1 mg and $499 for 2 mg (NovoCare Pharmacy, checked 28 Sep 2026). Ask your prescriber about coverage before looking elsewhere.

If you want semaglutide for weight management, Ozempic is not the comparison to make. Wegovy is the approved product for that, and our Wegovy comparison covers it.

A compounded vial is a reasonable fallback only when neither brand is reachable, and in diabetes it needs closer supervision: agreed glucose monitoring, a plan for insulin or sulfonylurea doses, and a prescriber who knows your HbA1c and eye history.